Edition:
United Kingdom

Xenon Pharmaceuticals Inc (XENE.OQ)

XENE.OQ on NASDAQ Stock Exchange Global Market

13.50USD
24 Sep 2018
Change (% chg)

-- (--)
Prev Close
$13.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
34,360
52-wk High
$15.90
52-wk Low
$2.15

Latest Key Developments (Source: Significant Developments)

Xenon Pharmaceuticals Announces Closing Of Its $63.0 Million Public Offering Of Common Shares
Monday, 17 Sep 2018 

Sept 17 (Reuters) - Xenon Pharmaceuticals Inc ::XENON PHARMACEUTICALS ANNOUNCES CLOSING OF ITS $63.0 MILLION PUBLIC OFFERING OF COMMON SHARES.  Full Article

Xenon Pharmaceuticals Announces Proposed Public Offering Of Common Shares
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Xenon Pharmaceuticals Inc ::XENON PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES.XENON PHARMACEUTICALS INC - HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON SHARES PURSUANT TO ITS EXISTING SHELF REGISTRATION STATEMENT.  Full Article

Xenon Expands Ion Channel Neurology Pipeline With Addition Of Xen496 For The Treatment Of Epilepsy
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - Xenon Pharmaceuticals Inc ::XENON EXPANDS ION CHANNEL NEUROLOGY PIPELINE WITH ADDITION OF XEN496, A “PHASE 3 READY” POTASSIUM CHANNEL MODULATOR FOR THE TREATMENT OF EPILEPSY.XENON PHARMACEUTICALS INC - SINGLE, PIVOTAL PHASE 3 CLINICAL TRIAL IN APPROXIMATELY 20 KCNQ2-EE PATIENTS EXPECTED TO BE INITIATED IN MID-2019.XENON PHARMACEUTICALS - FORMALLY ESTABLISHED STEERING COMMITTEE TO HELP GUIDE CLINICAL DEVELOPMENT OF XEN496.XENON - WORKING ON PEDIATRIC-SPECIFIC FORMULATION FOR XEN496 THAT MAY ALSO ADDRESS CERTAIN PIGMENTATION ISSUES ASSOCIATED WITH EZOGABINE.  Full Article

Xenon Announces Positive Xen1101 Pharmacodynamic Data From Phase 1B Tms Study
Wednesday, 29 Aug 2018 

Aug 29 (Reuters) - Xenon Pharmaceuticals Inc ::XENON ANNOUNCES POSITIVE XEN1101 PHARMACODYNAMIC DATA FROM PHASE 1B TMS STUDY.XENON PHARMACEUTICALS INC - XEN1101 PHASE 2 CLINICAL TRIAL IN ADULT FOCAL SEIZURES EXPECTED TO BE INITIATED IN Q4 OF 2018.XENON PHARMA - XEN1101 DEMONSTRATES STATISTICALLY SIGNIFICANT REDUCTION IN CORTICOSPINAL AND CORTICAL EXCITABILITY AS MEASURED BY TMS-EMG AND TMS-EEG.XENON - XEN1101 DEMONSTRATES GREATER EFFECT ON TMS-EMG RESTING MOTOR THRESHOLD AT SIGNIFICANTLY LOWER DOSE COMPARED TO HISTORICAL EZOGABINE DATA.XENON PHARMACEUTICALS - XEN1101 WAS WELL TOLERATED WITH ALL ADVERSE EVENTS REPORTED AS MILD OR MODERATE AND REVERSIBLE.XENON - COMPLETED ENROLLMENT IN XEN1101 PHASE 1 CLINICAL TRIAL USING A POWDER-IN-CAPSULE FORMULATION.  Full Article

Xenon Pharmaceuticals Reports Q2 Loss Per Share Of $0.45
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Xenon Pharmaceuticals Inc ::XENON PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.XENON PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.45.  Full Article

Xenon Pharmaceuticals Announces At-The-Market Equity Offering
Thursday, 12 Jul 2018 

July 12 (Reuters) - Xenon Pharmaceuticals Inc ::XENON PHARMACEUTICALS ANNOUNCES AT-THE-MARKET EQUITY OFFERING.XENON PHARMACEUTICALS INC SAYS ENTERED INTO AN AT--MARKET EQUITY OFFERING SALES AGREEMENT WITH JEFFERIES AND STIFEL, EFFECTIVE AS OF JULY 11, 2018.XENON PHARMACEUTICALS INC SAYS UNDER AT--MARKET EQUITY OFFERING SALES AGREEMENT, CO MAY SELL COMMON SHARES FOR UP TO $50.0 MILLION.  Full Article

Xenon Pharmaceuticals Entered At-The-Market Equity Offering Sales Agreement To Sell Shares Having Sales Proceeds Of Up To $50 Mln
Thursday, 12 Jul 2018 

July 12 (Reuters) - Xenon Pharmaceuticals Inc ::XENON PHARMACEUTICALS SAYS ON JULY 11, ENTERED INTO AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT TO SELL SHARES HAVING SALES PROCEEDS OF UP TO $50 MILLION.  Full Article

Xenon Pharmaceuticals Expects To Have Ongoing XEN1101 Phase 1 Clinical Trial Completed By Mid-Year
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Xenon Pharmaceuticals Inc ::XENON PHARMACEUTICALS OUTLINES KEY MILESTONES FOR 2018.XENON PHARMACEUTICALS INC - EXPECT TO HAVE ONGOING XEN1101 PHASE 1 CLINICAL TRIAL COMPLETED BY MID-YEAR.XENON PHARMACEUTICALS INC - IN SECOND HALF OF THIS YEAR, ANTICIPATE HAVING COMPLETED XEN901 PHASE 1 CLINICAL TRIAL.XENON PHARMACEUTICALS INC - ANTICIPATE THAT BOTH XEN1101 AND XEN901 COULD BE IN PHASE 2 DEVELOPMENT BY END OF THIS YEAR.XENON PHARMACEUTICALS INC - AS OF DECEMBER 31, 2017, CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $43.7 MILLION.XENON PHARMACEUTICALS INC - BASED ON CURRENT ASSUMPTIONS, XENON ANTICIPATES HAVING SUFFICIENT CASH TO FUND OPERATIONS INTO MID-2019.  Full Article

Xenon Pharma Says Entered Into Loan And Security Agreement With Silicon Valley Bank
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Xenon Pharmaceuticals Inc ::XENON PHARMACEUTICALS- ON DEC 18, CO, UNIT ENTERED INTO LOAN AND SECURITY AGREEMENT WITH SILICON VALLEY BANK - SEC FILING.XENON PHARMACEUTICALS - PURSUANT TO AGREEMENT, BANK AGREED TO EXTEND TERM LOANS TO CO WITH AGGREGATE PRINCIPAL AMOUNT OF UP TO $15 MILLION.XENON PHARMACEUTICALS INC - BORROWINGS UNDER LOAN AGREEMENT WILL CONSIST OF UP TO THREE SEPARATE TRANCHES.  Full Article

Xenon Pharmaceuticals reports Q3 loss per share $0.43
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Xenon Pharmaceuticals Inc :Xenon Pharmaceuticals reports third quarter 2017 financial results and provides corporate update.Q3 revenue $300,000 versus $400,000.Xenon Pharmaceuticals Inc - qtrly loss per share $0.43.  Full Article

BRIEF-Xenon Pharmaceuticals Q1 Net Loss Per Common Share $0.21

* XENON PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE